Cellular and molecular mechanisms of statins: an update on pleiotropic effects

被引:66
|
作者
Satoh, Mamoru [1 ]
Takahashi, Yuji [2 ]
Tabuchi, Tsuyoshi [3 ]
Minami, Yoshitaka [3 ]
Tamada, Makiko [3 ]
Takahashi, Kan [2 ]
Itoh, Tomonori [2 ]
Morino, Yoshihiro [2 ]
Nakamura, Motoyuki [3 ]
机构
[1] Iwate Med Univ, Inst Biomed Sci, Div Biomed Informat Anal, Morioka, Iwate, Japan
[2] Iwate Med Univ, Sch Med, Dept Internal Med, Div Cardiol, Morioka, Iwate, Japan
[3] Iwate Med Univ, Sch Med, Div Cardioangiol Nephrol & Endocrinol, Morioka, Iwate, Japan
基金
日本学术振兴会;
关键词
atherosclerosis; endothelial progenitor cells; miRNA; SIRT-1; telomere; toll-like receptor 4; ENDOTHELIAL PROGENITOR CELLS; ACUTE CORONARY SYNDROMES; HIGH-DOSE ATORVASTATIN; C-REACTIVE PROTEIN; NLRP3 INFLAMMASOME ACTIVATION; LIPID-LOWERING THERAPY; TOLL-LIKE RECEPTORS; METABOLIC SYNDROME; OXIDATIVE STRESS; CHOLESTEROL REDUCTION;
D O I
10.1042/CS20150027
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Coronary artery disease ( CAD) is the leading cause of death worldwide. The efficacy and safety of statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) in primary and secondary prevention of CAD are confirmed in several large studies. It is well known that statins have some pleiotropic, anti-atherosclerotic effects. We review the molecular mechanisms underlying the beneficial effects of statins revealed in recently published studies. Endothelial cell injury is regarded as the classic stimulus for the development of atherosclerotic lesions. In addition, the inflammatory process plays an important role in the aetiology of atherosclerosis. In particular, chronic inflammation plays a key role in coronary artery plaque instability and subsequent occlusive thrombosis. Our previous reports and others have demonstrated beneficial effects of statins on endothelial dysfunction and chronic inflammation in CAD. A better understanding of the molecular mechanism underlying the effectiveness of statins against atherosclerosis may provide a novel therapeutic agent for the treatment of coronary atherosclerosis. The present review summarizes the cellular and molecular mechanism of statins against coronary atherosclerosis.
引用
收藏
页码:93 / 105
页数:13
相关论文
共 50 条
  • [21] Understanding the molecular mechanisms of statin pleiotropic effects
    Charles A. German
    James K. Liao
    Archives of Toxicology, 2023, 97 : 1529 - 1545
  • [22] Understanding the molecular mechanisms of statin pleiotropic effects
    German, Charles A.
    Liao, James K.
    ARCHIVES OF TOXICOLOGY, 2023, 97 (06) : 1529 - 1545
  • [23] An update on statins: Pleiotropic effect performed in intracerebral hemorrhage
    Chen, Qianwei
    Zhang, Jianbo
    Feng, Hua
    Chen, Zhi
    ATHEROSCLEROSIS, 2019, 284 : 264 - 265
  • [24] Reply to: "An update on statins: Pleiotropic effect on intracerebral hemorrhage"
    Chung, Chang-Min
    Lin, Ming-Shyan
    Lin, Yu-Sheng
    ATHEROSCLEROSIS, 2019, 284 : 266 - 266
  • [25] Cellular and molecular mechanisms of hepatocellular carcinoma: an update
    Rajagopal N. Aravalli
    Erik N. K. Cressman
    Clifford J. Steer
    Archives of Toxicology, 2013, 87 : 227 - 247
  • [26] Cellular and molecular mechanisms of hepatocellular carcinoma: an update
    Aravalli, Rajagopal N.
    Cressman, Erik N. K.
    Steer, Clifford J.
    ARCHIVES OF TOXICOLOGY, 2013, 87 (02) : 227 - 247
  • [27] Stress on pleiotropic effects of statins - Reply
    Chello, Massimo
    Candura, Dario
    Mastrobuoni, Stefano
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2006, 29 (05) : 862 - 862
  • [28] Beneficial cardiovascular pleiotropic effects of statins
    Davignon, J
    CIRCULATION, 2004, 109 (23) : 39 - 43
  • [29] Pleiotropic effects of statins in atherosclerotic disease
    Pasterkamp, Gerard
    van Lammeren, Guus W.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (09) : 1235 - 1237
  • [30] The Pleiotropic Effects of Statins in Endocrine Disorders
    De La Cruz, Javier A.
    Mihos, Christos G.
    Horvath, Sofia A.
    Santana, Orlando
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2019, 19 (06) : 787 - 793